Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era
Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population. Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who t...
Published in: | The Lancet Regional Health - Europe |
---|---|
Main Authors: | , , , , , , , , , , , , , , , , |
Format: | Article in Journal/Newspaper |
Language: | English |
Published: |
2023
|
Subjects: | |
Online Access: | http://hdl.handle.net/10852/107082 https://doi.org/10.1016/j.lanepe.2023.100680 |
id |
ftoslouniv:oai:www.duo.uio.no:10852/107082 |
---|---|
record_format |
openpolar |
spelling |
ftoslouniv:oai:www.duo.uio.no:10852/107082 2024-02-11T10:05:02+01:00 Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era ENEngelskEnglishWere cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske 2023-09-18T18:02:46Z http://hdl.handle.net/10852/107082 https://doi.org/10.1016/j.lanepe.2023.100680 EN eng Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske . Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era. The Lancet Regional Health - Europe. 2023, 31 http://hdl.handle.net/10852/107082 2176226 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The Lancet Regional Health - Europe&rft.volume=31&rft.spage=&rft.date=2023 The Lancet Regional Health - Europe 31 0 https://doi.org/10.1016/j.lanepe.2023.100680 Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/ 2666-7762 Journal article Tidsskriftartikkel Peer reviewed PublishedVersion 2023 ftoslouniv https://doi.org/10.1016/j.lanepe.2023.100680 2024-01-24T23:39:44Z Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population. Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population. Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89–3.09; Denmark: 2.23, 1.96–2.54) and within five years (Norway: 1.58, 1.35–1.83; Denmark: 1.54, 1.42–1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors. Article in Journal/Newspaper Iceland Universitet i Oslo: Digitale utgivelser ved UiO (DUO) Norway The Lancet Regional Health - Europe 31 100680 |
institution |
Open Polar |
collection |
Universitet i Oslo: Digitale utgivelser ved UiO (DUO) |
op_collection_id |
ftoslouniv |
language |
English |
description |
Background In a population-based setting, we investigated the risks of testing positive for SARS-CoV-2 and developing severe COVID-19 outcomes among cancer patients compared with the general population. Methods In nationwide cohorts, we identified all individuals in Norway, Denmark and Iceland who tested positive for SARS-CoV-2 or had a severe COVID-19 outcome (hospitalisation, intensive care, and death) from March until December 2020, using data from national health registries. We estimated standardised incidence ratios (SIRs) with 95% confidence intervals (CIs) comparing cancer patients with the general population. Findings During the first wave of the pandemic, cancer patients in Norway and Denmark had higher risks of testing SARS-CoV-2 positive compared to the general population. Throughout 2020, recently treated cancer patients were more likely to test SARS-CoV-2 positive. In Iceland, cancer patients experienced no increased risk of testing positive. The risk of COVID-19-related hospitalisation was higher among cancer patients diagnosed within one year of hospitalisation (Norway: SIR = 2.43, 95% CI 1.89–3.09; Denmark: 2.23, 1.96–2.54) and within five years (Norway: 1.58, 1.35–1.83; Denmark: 1.54, 1.42–1.66). Risks were higher in recently treated cancer patients and in those diagnosed with haematologic malignancies, colorectal or lung cancer. Risks of COVID-19-related intensive care and death were higher among cancer patients. Interpretation Cancer patients were at increased risk of testing positive for SARS-CoV-2 during the first pandemic wave when testing availability was limited, while relative risks of severe COVID-19 outcomes remained increased in cancer patients throughout 2020. Recent cancer treatment and haematologic malignancy were the strongest risk factors. |
format |
Article in Journal/Newspaper |
author |
Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske |
spellingShingle |
Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
author_facet |
Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske |
author_sort |
Johansson, Anna L.V. |
title |
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
title_short |
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
title_full |
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
title_fullStr |
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
title_full_unstemmed |
Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era |
title_sort |
were cancer patients worse off than the general population during the covid-19 pandemic? a population-based study from norway, denmark and iceland during the pre-vaccination era |
publishDate |
2023 |
url |
http://hdl.handle.net/10852/107082 https://doi.org/10.1016/j.lanepe.2023.100680 |
geographic |
Norway |
geographic_facet |
Norway |
genre |
Iceland |
genre_facet |
Iceland |
op_source |
2666-7762 |
op_relation |
Johansson, Anna L.V. Skog, Anna Johannessen, Tom Børge Myklebust, Tor Åge Skovlund, Charlotte Wessel Mørch, Lina Steinrud Friis, Søren Gamborg, Mads Kristiansen, Marnar Fríðheim Pettersson, David Ólafsdóttir, Elínborg J. Birgisson, Helgi Palsson, Runolfur Eythorsson, Elias Irenaeus, Sandra Lambe, Mats Ursin, Giske . Were cancer patients worse off than the general population during the COVID-19 pandemic? A population-based study from Norway, Denmark and Iceland during the pre-vaccination era. The Lancet Regional Health - Europe. 2023, 31 http://hdl.handle.net/10852/107082 2176226 info:ofi/fmt:kev:mtx:ctx&ctx_ver=Z39.88-2004&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.jtitle=The Lancet Regional Health - Europe&rft.volume=31&rft.spage=&rft.date=2023 The Lancet Regional Health - Europe 31 0 https://doi.org/10.1016/j.lanepe.2023.100680 |
op_rights |
Attribution 4.0 International https://creativecommons.org/licenses/by/4.0/ |
op_doi |
https://doi.org/10.1016/j.lanepe.2023.100680 |
container_title |
The Lancet Regional Health - Europe |
container_volume |
31 |
container_start_page |
100680 |
_version_ |
1790601864841003008 |